Newsfeeds - Spark Newswire

5 minute read

The Daily Biotech Pulse: Lilly, Morphic’s Positive Data At ECCO, Humanigen’s COVID Treatment Gets Expedited Review In UK, TransCode IPO

Today, 3:47 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)

ABCL

11 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 3:47 PM

Thursday morning, 158 companies reached new 52-week lows.

ABCL

5 minute read

The Daily Biotech Pulse: Priority Review For Amgen’s Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test

By Shanthi Rexaline

Today, 3:47 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)

ABCL

2 minute read

One Year Following Single Administration, UniQure’s Hemophilia B Gene Therapy Candidate Shows Sustained Increase In Factor IX Levels

By Vandana Singh

Today, 3:47 PM

UniQure N.V. (NASDAQ:QURE) has announced 52-week data from its Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec to treat hemophilia…

QURE

1 minute read

UniQure Expands Gene Therapies Pipeline For Neurological Disorders With Corlieve Acquisition

By Vandana Singh

Today, 3:47 PM

UniQure N.V. (NASDAQ:QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common…

QURE

3 minute read

FDA
News

uniQure Reports 52-Week Clinical Data From HOPE-B Trial Of Hemophilia B Treatment Candidate: Showed ‘Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following…’

By Benzinga Newsdesk

Today, 3:47 PM

~ Sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal in full study population one year following a single administration of etranacogene dezaparvovec ~ ~ Held pre-BLA

QURE

4 minute read

uniQure To Buy Corlieve Therapeutics For €46.3M In Upfront Payment

By Benzinga Newsdesk

Today, 3:47 PM

~ Expands uniQure’s Pipeline of Innovative Gene Therapies to Treat Neurological Disorders ~ ~ Strengthens uniQure’s Global Leadership in the Development of Gene Therapies that Employ miRNA Silencing

QURE

1 minute read

News

uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

By Benzinga Newsdesk

Today, 3:47 PM

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first two patient procedures have been completed in the

QURE